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ABSTRACT
Objective: Rheumatoid arthritis (RA) is a multisystem,
inflammatory disorder associated with increased levels
of morbidity and mortality. While much research into
the condition is conducted in the secondary care
setting, routinely collected primary care databases
provide an important source of research data. This
study aimed to update an algorithm to define RA that
was previously developed and validated in the General
Practice Research Database (GPRD).
Methods: The original algorithm consisted of two
criteria. Individuals meeting at least one were
considered to have RA. Criterion 1: ≥1 RA Read code
and a disease modifying antirheumatic drug (DMARD)
without an alternative indication. Criterion 2: ≥2 RA
Read codes, with at least one ‘strong’ code and no
alternative diagnoses. Lists of codes for consultations
and prescriptions were obtained from the authors of
the original algorithm where these were available, or
compiled based on the original description and clinical
knowledge. 4161 people with a first Read code for RA
between 1 January 2010 and 31 December 2012 were
selected from the Clinical Practice Research Datalink
(CPRD, successor to the GPRD), and the criteria
applied.
Results: Code lists were updated for the introduction
of new Read codes and biological DMARDs. 3577/
4161 (86%) of people met the updated algorithm for
RA, compared to 61% in the original development
study. 62.8% of people fulfilled both Criterion 1 and
Criterion 2.
Conclusions: Those wishing to define RA in the
CPRD, should consider using this updated algorithm,
rather than a single RA code, if they wish to identify
only those who are most likely to have RA.
INTRODUCTION
Rheumatoid arthritis (RA) is a common
inﬂammatory multisystem disorder involving
joint inﬂammation, and increased morbidity
and mortality from related conditions, for
example, cardiovascular disease.1 Delays in
identifying and treating RA are common and
are associated with worse outcomes.
Research into RA has been focused in sec-
ondary care (eg, early arthritis clinics to
identify patients in the earliest stage of
disease). Algorithms and criteria to deﬁne
RA developed in secondary care settings
have also been developed. However, there
are likely to be aspects of the disease that it
is not possible to fully investigate in second-
ary care alone. For example, primary care
studies are likely to be needed to determine
healthcare usage prior to diagnosis,2 or
whether patients receive screening for dis-
eases for which they are at high risk.3
One potential way of investigating RA in
primary care is the use of healthcare data-
bases, for example the Clinical Practice
Research Datalink (CPRD), QResearch or
The Health Improvement Network (THIN).
Use of such databases in epidemiological
research is increasing, with CPRD data used
in over 190 studies in 2014.4 These data
sources include data recorded in routine
clinical practice, such as information regard-
ing symptoms, diagnoses, prescriptions and
referrals. These large databases are highly
generalisable, because they cover large
numbers of people from the general popula-
tion (eg, CPRD covers approximately 6% of
the UK population5), meaning that they can
be used efﬁciently in epidemiological
studies.
Strengths and limitations of this study
▪ An original, but out-of-date, definition of
rheumatoid arthritis derived from validated data
is updated.
▪ A large sample of high-quality, representative
primary care data was available to test the
updated algorithm.
▪ A comparison is made between the original def-
inition and the updated algorithm.
▪ The updated algorithm could not be compared to
full medical records.
Muller S, et al. BMJ Open 2015;5:e009309. doi:10.1136/bmjopen-2015-009309 1
Open Access Research
Use of these databases requires accurate identiﬁcation
of the conditions or treatments of interest. In the UK,
this is often carried out using a clinical coding system
such as Read codes, or for medications, British National
Formulary codes. However, the use of single codes is not
always suitably sensitive and/or speciﬁc and sometimes
more complex algorithms to deﬁne a disease or treat-
ment of interest are needed.
A deﬁnition has previously been developed to accur-
ately identify highly probable cases of RA in primary
care medical records,6 speciﬁcally in the General
Practice Research Database (GPRD, now the CPRD).
This deﬁnition used a combination of diagnostic Read
codes and prescription records to deﬁne a patient as
having or not having RA, achieving sensitivity of 84%
and speciﬁcity of 86%. However, this work was con-
ducted in data from 1987 to 2002 and since then the
Read code dictionary has been updated and extended,
and importantly, a new class of treatments for RA,
known as biologics, has been introduced. This means
that the original deﬁnition is now somewhat dated.
Therefore, the aim of this study was to describe our
updating of the deﬁnition of Thomas et al6 in order to
create an up-to-date algorithm to identify highly prob-
able RA cases in the CPRD and to compare the
characteristics of the algorithm to the original.
METHODS
The original Thomas algorithm to define RA
The original algorithm for RA was developed in the GPRD,
a predecessor to the current CPRD. In order to derive this
algorithm, 224 patients with at least one diagnostic Read
code for RA were randomly selected from the GPRD and
their full, anonymised medical records reviewed to ascertain
whether they did indeed have RA.6 Coded entries of symp-
toms, diagnoses and prescriptions were then assessed and
compared to the classiﬁcation of RA from the full notes
review, using a multivariable logistic regression model. This
resulted in the algorithm to deﬁne a case of RA (box 1).
Updating the Thomas algorithm
RA-related codes
Starting with the list of RA Read codes classiﬁed as
groups 1, 2, 3 and 4 by Thomas et al,6 the CPRD
Medical Dictionary was used to look up key terms asso-
ciated with each code (eg, ‘rheumatoid’, ‘felty’, ‘still’s’)
until all codes on the original list would have been
found if the code list remained the same. The new list
of codes was then reviewed, and using the original sever-
ity grouping as a guide, the new list of codes was
grouped by severity. This process was conducted by a
consultant rheumatologist (SLH) and a non-clinical
researcher (SM).
Drugs used to treat RA
The list of drugs considered to be used to treat RA in
the original algorithm was not available from the
authors. Therefore, the British National Formulary
(BNF) was reviewed to identify all drug speciﬁed as
being for the treatment of ‘rheumatoid arthritis and
other inﬂammatory disorders’ within the musculoskel-
etal system and joint diseases chapter. This list was then
reviewed by SLH to ascertain whether this list covered
all drugs used in clinical practice and that all of the
drugs identiﬁed were relevant to RA. Oral steroids and
non-steroidal anti-inﬂammatory drugs were excluded, as
they were treated separately when the original algorithm
was developed, and were found to be insufﬁciently spe-
ciﬁc to a diagnosis of RA.6
Alongside this list of potential RA treatments, which
consisted of conventional and biological disease modify-
ing antirheumatic drugs (DMARDs), a list of potential
alternative indications each for these treatments was
compiled from the BNF. Synonyms for these conditions
were then established and the CPRD Medical Browser
used to assemble a list of potentially relevant codes,
which was reviewed by SLH and CDM (professor of
general practice), and consensus reached.
Alternative diagnoses
As with drugs used to treat RA, a list of codes that would
indicate a diagnosis that supersedes RA was not available
from the authors of the original algorithm. Therefore, a
list of potential conditions and their synonyms was
reached by consensus between SLH and CDM. The
CPRD Medical Browser was searched for these terms to
establish a list of codes and related terms, which was then
reviewed by SLH and CDM in order to determine a ﬁnal
list of codes indicating an alternative diagnosis to RA.
Study sample
For this study, a sample of all individuals with a ﬁrst
RA-related Read code (codes in groups 1–4, as deﬁned
above) between 1 January 2010 and 31 December 2012,
was obtained from the CPRD. RA status was determined
according to the deﬁnition described above (box 1).
The full period of the record held by the CPRD was
downloaded for all individuals in the sample, before and
after their ﬁrst RA code.
Box 1 Thomas et al6 algorithm for rheumatoid arthritis
(RA) in the General Practice Research Database
Criterion 1: At least one diagnostic Read code for RA and at least
one appropriate prescription of a disease modifying antirheumatic
drug (DMARD) with no alternative indication for the DMARD;
or
Criterion 2: all three of the following:
a) two or more diagnostic Read codes for RA (on different dates);
b) no alternative diagnosis after the final RA code;
c) RA code in group 1 (seropositive or erosive RA) or group 2
(‘rheumatoid arthritis’ codes eg, RA of knee), opposed to only
group 3 (systemic manifestations of RA) or group 4 (seronega-
tive RA or other weak evidence of RA).
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Statistical analyses
Absolute numbers and percentages were used to show
the proportion of people with an RA code who were sub-
sequently deﬁned as having ‘deﬁnite’ RA according to
the updated algorithm. Analyses were repeated separ-
ately in gender-speciﬁc and age-speciﬁc groups
(grouped roughly into quartiles according to the distri-
bution in the data: <50 years; 50–59 years; 60–69 years;
≥70 years) and year of ﬁrst RA code.
Analyses were repeated for individual criteria within
the algorithm for RA.
RESULTS
Updated lists of Read codes to apply in Thomas algorithm
RA-related codes
The search of key terms from the original list of Read
codes produced a larger number of codes. Some codes
were not relevant and were excluded (eg, family history
of RA). Of the remaining codes, some had the same
attached terms as codes in the original list, while others
were new, and clinical judgement (SLH/CM) was used
to assign them to a severity group.
DMARDs used to treat RA
A full list of the DMARDs licensed for the treatment of
RA in the UK at the time of the study ( January 2014),
was compiled from the BNF. The other licensed uses or
alternative indications for these drugs were assessed
using the BNF. ‘Alternative indications’ for these
DMARDs varied by substance, but included psoriatic
arthritis, seronegative spondyloarthropathy, juvenile idio-
pathic arthritis, psoriasis, inﬂammatory bowel disease,
systemic lupus erythematosus, transplant, vasculitis, leu-
kaemia and lymphoma. Code lists to deﬁne each of
these conditions were formulated, with consensus on the
ﬁnal list reached between SLH and CDM.
Alternative diagnoses
Alternative diagnoses to RA (ie, those which if present
after the ﬁnal RA code in the record would supersede a
diagnosis of RA), were decided to be psoriatic arthritis,
ankylosing spondylitis and other spondyloarthropathies.
Polymyalgia rheumatica (PMR) was also considered as a
potential alternative diagnosis, as RA would be an alter-
native diagnosis for PMR. However, it was decided that
as PMR is often considered a diagnosis of exclusion, this
was not appropriate.
Full lists of the codes used to deﬁne RA, DMARDs and
their alternative indications and alternative diagnoses
are available from the clinicalcodes.org website and in
the authors’ institutional repository (keele.ac.uk/mrr).
Searches for appropriate codes to implement the algo-
rithm were conducted in all available data for each
individual.
Proportion of those with RA code considered to have
definite RA
Between 2010 and 2012, 4161 people were identiﬁed in
the CPRD as having a ﬁrst Read code for RA. The
median length of time from the index date (date of ﬁrst
RA code) to the ﬁnal consultation in the record of these
patients was 3.25 years (IQR 2.5, 4.1), and the median
length of the consultation record prior to the index date
was 37.7 years (25.4, 49.0). Of these, 3577 (86%) were
considered to have deﬁnite RA according to the
updated algorithm (table 1). A total of 659 (15.8%)
people met only the ﬁrst criterion of a DMARD with no
alternative indication. A total of 304 (7.3%) people satis-
ﬁed the second set of criteria only (ie, ≥2 RA codes on
separate dates, no alternative diagnosis after ﬁnal RA
code and an RA code in severity group 1 or 2). A total
of 2614 (62.8%) people met both sets of criteria.
Males and females with an RA code were equally likely
to meet the deﬁnition of RA (p=0.369; table 2). There
was however a difference in the rate of ‘deﬁnite diagno-
sis’ across age groups, with those aged 60–69 years most
likely to meet the deﬁnition (88%), and those aged
Table 2 Fulfilment of the RA definition by age and
gender
n (%) All Males Females
All 3577 (86.0) 1188 (85.3) 2389 (86.3)
<50 years 902 (83.8) 231 (81.1) 671 (84.8)
50–59 years 786 (87.6) 225 (88.9) 561 (87.1)
60–69 years 942 (88.0) 356 (87.9) 586 (88.1)
≥70 years 947 (84.7) 376 (83.6) 571 (85.5)
RA, rheumatoid arthritis.
Table 1 Fulfilment of each RA definition by the sample,
compared to Thomas et al6 in GPRD
Thomas
et al6
N=31 830
Current
sample
N=4161
Database GPRD CPRD
Time frame 1987–2002 2007–2012
Age of sample ≥16 years ≥18 years
Criterion 1: appropriate
DMARD prescription
15 746 (49) 3273 (78.7)
Criterion 2: all 3 of the
following
– 2918 (70.1)
>1 RA code during
follow-up
16 300 (51) 3230 (81.5)
No alternative diagnostic
code after last RA code
27 184 (85) 4109 (98.8)
≥1 RA code in group 1 or 2 27 738 (87) 3535 (89.2)
Full diagnostic algorithm
(criterion 1 and/or criterion 2)
19 492 (61) 3577 (86.0)
–, Data not available.
CPRD, Clinical Practice Research Datalink; DMARD, disease
modifying antirheumatic drug; GPRD, General Practice Research
Database; RA, rheumatoid arthritis.
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<50 years least likely (83.8%) (p=0.010). Similar patterns
were seen across age groups within each gender as were
seen overall, although males were most likely to have
deﬁnite RA in the 50–59 years age group. On the whole,
the proportion of people with a single RA code meeting
the updated deﬁnition of RA was relatively stable across
the 3 years included in this study, although the deﬁn-
ition of RA was less likely to be met in those receiving
their ﬁrst RA code in 2011 (88%), with slightly lower
rates of conﬁrmed diagnosis in earlier and later years
(p=0.029). This difference is driven by a combination of
differences in the number of people with a suitable
DMARD and the number of people with multiple RA
codes (table 3).
DISCUSSION
Accurate diagnosis of RA is of paramount importance
clinically, as current guidelines recommend early and
aggressive treatment with DMARDs. In order to take this
approach clinically, further research will be necessary to
accurately identify patients with RA in primary care. This
updated algorithm could contribute to this research.
Without suitable means of deﬁning an RA cohort that
has a high probability of being true RA, such studies
would be of poorer quality. This study has updated the
deﬁnition, initially proposed by Thomas et al,6 to deﬁne
RA in the GPRD for use in the CPRD. The original
authors of this deﬁnition stated that the use of their
algorithm prior to 2002 appeared to be valid, but that it
would need to be updated for future work, speciﬁcally
around the use of biological therapies. The current
study has made this update, without unnecessarily com-
plicating the algorithm by attempting to recreate it from
ﬁrst principles. Using this updated algorithm, 86% of
people with a code for RA were considered to have ‘def-
inite’ RA.
Thomas et al6 studied 258 people aged 16 years and
over with a code for RA in the GPRD. After correspond-
ence with the patients’ general practitioners (GPs) and
review by expert rheumatologists, they considered 125
(48%) of these people to have deﬁnite RA. We could
not make this comparison in the current study, as we did
not have access to full medical records for people with
an RA Read code. Hence, we are not able to report
formal assessments of the algorithm’s performance,
such as sensitivity or speciﬁcity. Instead, the current
study sought to update the algorithm previously devel-
oped by Thomas et al6 and compare it to the original. In
the original study, the authors found that of the 31 830
people that they identiﬁed as having an RA code in
their GPRD record, 61% met the deﬁnition of RA. This
compares to 86% in the current study, suggesting that
the updated algorithm may be more sensitive, or less
speciﬁc than the original. However, we believe that this
higher rate of conﬁrmed RA diagnoses may reﬂect
changes in coding practice over time, or that GPs are
less willing to code RA in the medical records until the
diagnosis is conﬁrmed by a specialist. This may mean
that a single code for RA is now a more accurate reﬂec-
tion of a true diagnosis of RA than was previously the
case.
Consideration of the speciﬁc elements of the deﬁn-
ition, in comparison to the work of Thomas et al showed
that the largest difference came from the proportion of
people with a record of a DMARD with no alternative
indication. This criterion, which in the presence of a
single RA Read code, was sufﬁcient to classify someone
as having deﬁnite RA, was met by 78.7% of the current
sample, opposed to 49% of Thomas et al’s6 sample. This
may reﬂect the updated list of DMARD codes in the
current study, but given the different time frames of the
data sets, is likely due to the move to transfer repeat pre-
scribing of DMARDs from secondary to primary care in
the UK. The current study also saw a substantial increase
in the number of people with more than one RA code
in the study period (51% vs 81.5%), and indeed this
increase may be larger than it ﬁrst appears, when the
length of follow-up time in the studies is considered; up
to 5 years in the current study compared to up to
16 years in the original. It seems likely that the increase
in DMARD recording and the number of RA codes,
combined with an increase in the number of people
without an alternative diagnosis after their ﬁnal RA
code, reﬂects general changes in coding practice, with
codes becoming more speciﬁc and less likely to be
entered into the record until GPs are conﬁdent of the
diagnosis. It could also reﬂect a change in the diagnostic
process used by rheumatologists since the introduction
of the 2010 American College of Rheumatology/
Table 3 Fulfilment of the RA definition by year of first RA code
n (%)
Full diagnostic
algorithm Criterion 1 Criterion 2
>1 RA code
during follow-up
No alternative diagnostic
code after last RA code
≥1 RA code in
group 1 or 2
2010 1204 (84.6) 1101 (77.4) 967 (68.0) 1050 (79.9) 1404 (98.7) 1186 (90.3)
2011 1186 (88.0) 1096 (81.3) 969 (71.9) 1068 (82.0) 1327 (98.4) 1173 (90.0)
2012 1187 (85.4) 1076 (77.4) 982 (70.7) 1112 (82.7) 1378 (99.1) 1176 (87.4)
p Value 0.029 0.016 0.068 0.163 0.246 0.033
Full algorithm requires meeting either criterion 1 or criterion 2 (or both); criterion 2 requires having (a) >1 RA code during follow-up and (b) no
alternative diagnostic code after last RA code, and (c) ≥1 RA code in group 1 or 2.
RA, rheumatoid arthritis.
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European League Against Rheumatism classiﬁcation cri-
teria for RA,7 which mean that rheumatologists are likely
to diagnose RA earlier in the disease course, and there-
fore GPs may in turn code it earlier. Similarly, the intro-
duction of the National Institute for Health and Care
Excellence Rheumatoid Arthritis Guideline in 2009
should have prompted faster referral by GPs of sus-
pected patients with RA to secondary care. Thereby
speeding up, and potentially increasing the accuracy of
the diagnoses recorded in primary care records such as
the CPRD.
However, we cannot rule out the possibility that
changes over time in coding practice and in the man-
agement of RA could mean that the necessary compo-
nents of a deﬁnition of RA may have changed, and we
did not consider this in the current study. For example,
in the original study, Thomas et al6 considered joint
symptoms/investigation codes after the ﬁrst RA code,
and the presence of two or more non-steroidal anti-
inﬂammatory prescriptions in a 6-month period as
potential predictors of true RA, but they were not con-
sidered optimal for the ﬁnal model. To recreate the
whole process from the original formulation of this def-
inition of RA would be hugely intensive in terms of
ﬁnancial and human resource, and seems unlikely to
yield a vastly different model. The current study there-
fore presents a necessary and efﬁcient update to the
existing work in this area that can be readily applied in
research practice.
For the reasons discussed above, those wishing to
apply the updated algorithm should do so with caution,
particularly in the situation where a highly sensitive def-
inition of RA is required (eg, prevalence study, clinical
audit). The current algorithm is likely to be unsuitable
for such studies, as it is designed to ﬁnd those with
highly probable RA. Indeed, if changes in coding prac-
tice have occurred in the manner discussed above, with
GPs more certain of a diagnosis before entering a code,
the updated algorithm may be more speciﬁc than the
original. Before the algorithm is used in settings where a
less speciﬁc deﬁnition of RA is required, it would be
sensible to formally test its performance, by comparing
to full medical records, as was the case in its original
development. However, this was beyond the scope of the
current study.
In addition to the potential weaknesses of this study
discussed above, there are some limitations to the use of
clinical databases in general that should be considered
in all such studies. These include a reliance on what is
coded by the general practice, which may be different to
the patient’s perception of the consultation, and indeed
may not reﬂect the entire content of a consultation.
This is particularly the case when considering symptoms,
opposed to clear-cut diagnoses, but is less of a problem
with prescriptions, which are generally issued electronic-
ally and therefore recorded by default. In addition, it is
usually not possible to understand the reasons for a par-
ticular diagnostic code or prescription being recorded
and one must rely on what is in the record having been
a true event and accept that anything that is not present
did not happen.
Our investigation of the proportion of people fulﬁlling
the deﬁnition RA according to the year was intended to
investigate the algorithm’s stability over time. However, it
also gave some insight into the time required to fulﬁl
the criteria (eg, second RA code). The stability of the
proportion fulﬁlling the deﬁnition over time suggests
that 12 months seems a reasonable time frame in which
to consider follow-up after the ﬁrst RA code, in order to
apply this deﬁnition.
If GPs are waiting to code a diagnosis of RA until
they are conﬁdent that this is the correct diagnosis,
for example, when it is conﬁrmed by a specialist, this
has implications for studies requiring a ‘start time’
when a condition was suspected by the GP, for
example, those wishing to look at care pathways, or
early symptoms, the time of the ﬁrst diagnostic code
will be much later than the period of real interest.
This is issue that has already been raised by others,2 8
and indeed was investigated in relation to RA by
Nicholson et al2 who suggested a range of ‘indicator
markers’ for early inﬂammatory arthritis. This is some-
thing that researchers may wish to consider in apply-
ing this new updated algorithm for RA in practice,
dependent on their research question.
This updated algorithm for RA in the CPRD could be
applied in other studies in the CPRD and indeed in
other databases. Researchers should be aware of the
follow-up time available after an RA code in which an
individual can fulﬁl the deﬁnition of RA. Further
research in this ﬁeld, should resources allow, might con-
sider testing this updated algorithm for RA against full
medical records.
A strength of the current study was that it was careful
to exclude the period when RA was included in the
Quality and Outcomes Framework (QOF) a set of
quality standards by which UK GPs receive some of their
funding. In 2013–2014, RA was included in the QOF,
requiring GP to maintain a register of patients, provide
them with a face-to-face review and dependent on their
age, screen them for cardiovascular disease and fracture
risk. This package of care was worth 18 QOF points. In
the following and subsequent years, this was reduced to
only the register and review and worth only six points.
The inclusion of a condition in QOF has this has been
known to alter the way in which GPs code the conditions
and indeed we found that the number of individuals
with a new RA code was considerably higher in 2013–
2014 than in the years before or after. Future studies
should exercise caution if including this 1 year period in
their work, as the algorithm has not been tested in this
setting.
Although diagnoses recorded in the CPRD have
been shown in general to be valid,9 further work to
develop deﬁnitions of speciﬁc conditions should be
compiled and made openly available. This would
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increase the credibility of work in the ﬁeld and enable
more effective use of these rich resources, especially
where diagnosis and/or management is largely
primary care based.
This study has updated a deﬁnition of RA in a large
representative database of primary care medical records
from the UK, which can be applied in a range of
studies, where this condition is a key outcome or expos-
ure, or indeed where it is of interest as a confounding
or effect modifying factor. Future studies of RA in
primary care databases should use this updated deﬁn-
ition, rather than the original version.
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